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Abstract
Reports from large studies using administrative datasets and event registries have characterized
recent temporal trends and treatment patterns for AMI. However, few are population-based and
fewer have examined differences in patterns of treatment for patients presenting with ST elevation
myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). We
examined 22-year trends in the use of 10 medical therapies and procedures by STEMI and
NSTEMI classification in 30986 definite or probable MIs in the ARIC Community Surveillance
Study from 1987 to 2008. We used weighted multivariable Poisson regression controlling for sex,
race/center classification, age, and PREDICT score to estimate average annual percent changes in
medical therapy use. From 1987 – 2008, 6106 (19.7%) hospitalized events were classified as
STEMI, and 20302 (65.5%) were classified as NSTEMI. Among STEMI patients, increases (%;
95% CI) were noted in the use of ACE inhibitors (6.4; 5.7, 7.2), non-aspirin anti-platelets (5.0;
4.0, 6.0), lipid-lowering medications (4.5; 3.1, 5.8), beta blockers (2.7; 2.4, 3.0), aspirin (1.2; 1.0,
1.3), and heparin (0.8; 0.4, 1.3). Among NSTEMI patients, the use of ACE inhibitors (5.5; 5.0,
6.1), non-aspirin anti-platelets (3.7; 2.7, 4.7), lipid-lowering medications (3.0; 1.9, 4.1), beta
blockers (4.2; 3.9, 4.4), aspirin (1.9, 1.6; 2.1), and heparin (1.7; 1.3, 2.1) increased. Among
STEMI patients, we observed decreases in the use of thrombolytics (-7.2; -7.9, -6.6) and CABG
(-2.4%; -3.6, -1.2). We noted similar increases in PCI and decreases in the use of thrombolytics
© 2012 Excerpta Medica, Inc. All rights reserved.
Corresponding Author Contact Information: Emily O'Brien, PhD Duke Clinical Research Institute 2400 Pratt Street Durham, NC
27705 Phone: 919-668-0670 emily.obrien@duke.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Am J Cardiol. Author manuscript; available in PMC 2014 June 30.
Published in final edited form as:






















and CABG among all patients. In conclusion, we found trends of increasing use of evidence-based
therapies for both STEMI and NSTEMI patients over the past 22 years.
Keywords
Epidemiology; myocardial infarction; treatment patterns; reperfusion; temporal trends
Introduction
The availability of medical therapies for in-hospital management of AMI is increasing
annually1,2, and the use of these therapies has substantially contributed to the decreasing
AMI death rates over the past three decades.3-7 Reports from large observational studies
have characterized recent temporal trends and treatment patterns for AMI.8-11 Conclusions
from existing reports have been limited, however, by selection, short follow-up periods,
racially and/or geographically homogenous populations, and unvalidated clinical data.
Furthermore, few studies have examined differences in temporal trends in the treatment of
patients presenting with ST elevation myocardial infarction (STEMI) versus non-ST
elevation myocardial infarction (NSTEMI), especially since this redefinition of acute MI
resulted in a divergence in treatment recommendations by MI subclass beginning in 2000.12
This report characterizes temporal trends in the in-hospital treatment of STEMI and
NSTEMI patients over a 22-year period in the Atherosclerosis Risk in Communities (ARIC)
Study.
Methods
The design of the community surveillance component of the Atherosclerosis Risk in
Communities (ARIC) study has been described.13,14 Briefly, it is a continuous retrospective
surveillance study of hospitalized coronary heart disease (CHD) events with mortality
follow-up designed to estimate trends in CHD incidence and mortality using standardized
criteria and methods in four U.S communities: Forsyth County, NC; Jackson, MS; eight
suburbs of Minneapolis, MN; and Washington County, MD. Eligible events included
inpatient and out-of-hospital deaths due to CHD and hospitalized nonfatal MI in 35-74 year
old residents of these communities. Trained abstractors investigate hospitalizations
randomly sampled from annual discharge lists obtained from each hospital serving the four
ARIC communities. Events were sampled on age, gender, community of residence and
International Classification of Diseases (ICD-9) discharge codes, including 402, 410-414,
427, 428, and 518.4. Collected data items included presenting symptoms; timing of
symptom onset; history of MI, angina, and other cardiovascular conditions; in-hospital
medications, diagnostics, and medical procedures; laboratory values for a number of
relevant cardiac biomarkers; and up to 3 sets of twelve-lead ECG readings. Regular and
ongoing inter-abstractor agreement is assessed by evaluating concordance between data
elements from a sample of cases abstracted independently by two abstractors. Internal
quality control procedures at the ECG reading Center were utilized to ensure reproducibility.
A computerized algorithm using electrocardiogram readings, history of chest pain, and
cardiac biomarker levels (total creatinine phosphokinase (CK), creatinine phosophokinase-
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myocardial band (CK-MB), lactate dehydrogenase (LDH), troponin I, and troponin T) was
used to assign an MI diagnosis to sampled hospitalized events. This analysis was restricted
to events with a Definite or Probable MI diagnosis. Any event with abnormal or equivocal
biomarker levels was further classified as ST- or non-ST elevation MI using pain
presentation and Minnesota-coded electrocardiogram data from the first, third, or last ECG
performed during hospitalization. Multiple hospitalizations occurring within 28 days were
combined and treated as one event. Any event requiring review (for example, events where
the computer-derived classification of definite MI disagreed with the ICD-9-CM codes for
discharge diagnosis) was independently classified by two trained reviewers. Any
disagreements in diagnoses were then adjudicated by a third reviewer.
Medications and procedures were obtained from hospital pharmacy records and medical
record review during the abstraction process. Our analysis included data on 7 medication
classes: aspirin, beta blockers, calcium channel blockers, angiotensin-converting enzyme
(ACE) inhibitors, lipid-lowering medications, non-aspirin anti-platelet agents, and heparin;
and 4 revascularization procedures: coronary artery bypass grafting (CABG), thrombolytic
therapy (intracoronary or intravenous streptokinase, urokinase, anistreplase, anisoylated
plasminogen streptokinase activator complex [APSAC], or tissue plasminogen activator
[TPA]), and coronary angioplasty (PCI) with or without the implantation of a stent. Each
medication or procedure was classified as any receipt during hospitalization or at discharge
(yes or no). Because abstraction of several therapies of interest began after 1987, trends for
the following therapies were estimated beginning with the first study year for which
complete treatment information was available for all sampled events: heparin (beginning in
1992), ACE inhibitors (1992), non-aspirin anti-platelets (1997), lipid-lowering medications
(1999) and stent implantation (1999).
Patient demographics were obtained from medical record reviews. Demographics of interest
included gender (male or female), race (black or white/other) and age. Clinical
comorbidities including prior MI, hypertension, diabetes mellitus, and stroke were collected.
In order to adjust for disease severity and clinical comorbidity, we utilized a modified
Predicting Risk of Death in Cardiac Disease Tool (PREDICT) score.15 The score is a
validated metric that predicts mortality in acute coronary syndrome patients from clinical
presentation data, including cardiogenic shock, history of MI or cardiac procedures, age,
severity of electrocardiographic changes, congestive heart failure, and Charlson
Comorbidity Index. Data on renal function were not collected and therefore were omitted
from our PREDICT score calculation.
We excluded patients whose race was not classified as black or white (n=658) and due to
insufficient sample sizes, black patients who were sampled in Minnesota or Washington
County, Maryland (n=493). After these exclusions, the final sample size for analysis was
30,986 definite or probable MI events.
All estimates presented are weighted to account for the ARIC surveillance sampling
scheme.13 We examined changes in study population characteristics over the study period
using chi-square tests for independence with robust variance estimation to account for the
complex sampling scheme. The proportion of patients receiving each medication and
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procedure were calculated for all study years using weighted Poisson regression, with
estimates age-standardized to the 2000 US Census age distribution. We used multivariable
loglinear regression to estimate average annual percent increases or decreases for each
medical therapy overall and among STEMI and NSTEMI patients. In the figures, we present
medication and procedure use for each study year; however, for ease of reporting and to
promote stability in confidence interval estimates, events were grouped into intervals of 5, 6,
or 7 years for table presentation. To account for the complex sampling scheme, all analyses
were conducted using SAS-callable SUDAAN (release 9.2; Research Triangle Institute,
Research Triangle Park, North Carolina).
Results
Table 1 shows selected study population characteristics over time in 5-year intervals. From
1987 to 2008, 30,986 definite or probable MI events were sampled in the four study
communities. Of these, 6106 (19.7%) were classified as STEMI, and 20302 (65.5%) were
classified as NSTEMI. The proportion of patients classified as neither STEMI nor NSTEMI
(14.8%) remained stable over the study period, as did gender and age distribution. Mean
length of stay in days (95% CI) decreased substantially over the study period, as did the
prevalence hypertension, diabetes, and stroke all increased throughout the study period.
Table 2 presents the proportion of patients receiving each medication and procedure of
interest by year, age-standardized to the 2000 US Census population. We observed increases
in the use of all medications and procedures except for calcium channel blockers and
thrombolytic therapy, both of which decreased throughout the study period. Data on the use
of stents was first collected in 1998. Since then, the proportion of all MI patients receiving
stents doubled. Temporal trends for all patients and for STEMI/NSTEMI patients are
illustrated for selected medications and procedures in Figure 1.
Figure 2 presents the average annual percentage change in the use of 7 medications and 4
procedures in ARIC surveillance from 1987-2008 by STEMI and NSTEMI classification,
adjusted for sex, age, race*center classification, and PREDICT score. (Note: a reported
percent change of 5% indicates an increase of 5% per year on average in the use of that
particular medication or procedure during the study period). Similar trends were seen among
STEMI and NSTEMI patients: increases (%) were noted in the use of ACE inhibitors, non-
aspirin anti-platelet agents, lipid-lowering medications, beta blockers, aspirin, and heparin,
Calcium channel blocker use decreased for both STEMI and NSTEMI patients over the
study period. Temporal trends in the receipt of reperfusion and revascularization procedures
were also similar for STEMI and NSTEMI patients. There were decreases in the use of
thrombolytics and CABG. PCI and stent use increased for both STEMI and NSTEMI
patients.
Finally, we examined reperfusion and revascularization rates in in male and female STEMI
and NSTEMI patients. Risk ratios and 95% CIs comparing receipt of any reperfusion/
revascularization strategy (PCI, PCI with stent, CABG, or thrombolytics) among men versus
women for each study year are shown in Figure 3. Crude rates of reperfusion/
revascularization were higher among men than among women for all study years. However,
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after adjustment for age, race*center, PREDICT score, and STEMI/NSTEMI classification,
we did not observe significant differences in rates of revascularization across gender strata.
Discussion
This is the first study to present long-term trends in-hospital treatment for both STEMI and
NSTEMI patients using validated clinical data. The ARIC community surveillance study
offers several advantages in the estimation of in-hospital MI treatment trends, including its
large, geographically and racially diverse population, 22 years of follow-up, population-
based sampling scheme, and detailed clinical event data and validated MI diagnostics.
We observed an increase in the use of 6 of 7 medications over the study period among
STEMI and NSTEMI patients. The largest increases were in ACE inhibitors, non-aspirin
anti-platelets, lipid-lowering medications, and beta-blockers. Smaller increases were noted
for aspirin and heparin. These increases were significant after adjustment for age, gender,
race and study center, and PREDICT score, did not differ by MI subclass, and are consistent
with findings from other populations documenting increases in the use of aspirin10,11,16,
beta-blockers8,10,11, and ACE inhibitors8,10,11,17_ENREF_6. Calcium channel blockers
were the only class of medications for which we observed a decrease. The magnitude of
decrease was similar to that reported in other populations.8,11 The overall results of
increasing use of evidence-based pharmacological interventions for hospitalized MI are
consistent with those of other studies reporting trends in increasing quality of care and better
guideline adherence for acute MI patients.18,19
A number of studies of revascularization in AMI conducted in the early 1990's reported
persistent gender disparities in the receipt of PCI, CABG, and/or thrombolytics.20-22 We
compared receipt of any revascularization strategy among men and women over the study
period. Crude estimates indicated that men were more likely than women to receive
revascularization at all time points. However, after adjustment for age, race*center,
PREDICT score and STEMI classification, we no longer observed significant differences in
the use of any revascularization strategy in women compared to men. These findings are
consistent with those of several studies that suggest gender differences in revascularization
rates may be accounted for by other clinical variables and event characteristics.23-25
This study also presents trends in pharmaceutical treatments and reperfusion procedures by
MI subclass. NSTEMI and STEMI were introduced as subclasses for acute MI in 2000.26
While both STEMI and NSTEMI release markers of necrosis that reflect acute MI, a
classification of STEMI indicates transmural myocardial ischemia or necrosis as evidenced
by ST-elevation electrocardiographic data. Few studies have examined long-term trends in
management of NSTEMI and STEMI. Data from the National Registry of Myocardial
Infarction (1990-2006) reported similar improvements in quality of care over the study
period for STEMI and NSTEMI patients.18
PCI use increased markedly among STEMI patients after 1999, contemporaneous to the
publication of the AHA 1999 Update to Guidelines for the Management of Patients with
Acute Myocardial Infarction, which recommended balloon inflation for PCI within 90
O'Brien et al. Page 5






















minutes of hospital arrival for eligible patients. The use of thrombolytics increased after the
1987-1990 time period for both STEMI and NSTEMI patients, concurrent with the
publication of results from two European trials, GISSI (1986) and ISIS-2 (1988), which
reported mortality reductions with thrombolytics compared to placebo.27,28 However, the
use of thrombolytics declined sharply after 1994, following the publication of a number of
trials reporting better clinical outcomes among patients treated with angioplasty compared to
those treated with thrombolytics.29_ENREF_30
This study has a number of limitations. First, because the structure of the medication data
element captures medications prescribed at any point during hospitalization or at discharge,
we did not have information on timing of administration. This limited our ability to make
comparisons between early or delayed medication use. We were also unable to distinguish
between medication use during hospitalization and at discharge. An additional limitation of
this study is the possibility of confounding by indication. Because we do not have data on
eligibility for each medication of interest, we were unable to examine the impact of patient-
specific indications on temporal trends in MI therapy. However, we did assess changes in
the comorbidity burden in this population by analyzing temporal trends in mean PREDICT
score, a validated score that includes a comorbidity index and clinical event data. We did not
observe significant changes in mean PREDICT score over time for among STEMI or
NSTEMI patients.
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Medication and procedure use by year in STEMI and NSTEMI patients in the ARIC
surveillance study: 1987 – 2008.
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Average annual % change in medical therapy and reperfusion procedure use in STEMI and
NSTEMI patients in the ARIC surveillance study: 1987 – 2008.
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Adjusted and unadjusted temporal trends in risk ratios comparing receipt of any reperfusion
strategy in men versus women in the ARIC surveillance study: 1987 – 2008.
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